NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Artios Pharma

Artios Pharma

Private
CambridgeHealthcare & Life Scienceshttps://www.artios.com/

Last Round

Series D

Nov 17, 2025

Total Funding Raised

$500.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Artios Pharma is a biotechnology company developing a pipeline of cancer treatments that target the DNA Damage Response (DDR) process.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

DNA damage responseDDRoncology pipelinecancer drug discoverysmall molecule inhibitorssynthetic lethalityclinical stage biotechbiotech startupDNA polymerase theta inhibitorATR inhibitorprecision oncologytargeted cancer therapybiopharma partnershipdrug developmentclinical trials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Artios Pharma Comparables

Compare Artios Pharma with similar companies based on industry and business-model similarity.

Artios Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Repare Therapeutics
82%
FoRx Therapeutics
79%
Breakpoint Therapeutics
79%

Artios Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DNov 17, 2025
Series DNov 17, 2023
Series CJul 27, 2021
Series BAug 10, 2018
Series ASep 21, 2016

Artios Pharma Investors

Notable investors and investment history

Artios Pharma investors
InvestorRounds
Soleus CapitalSeries C
Janus Henderson GroupSeries D
RA Capital ManagementSeries D
TCG CrossoverSeries C
Omega FundsSeries D, Series C
EQT Life SciencesSeries D, Series C, Series B
SV Health InvestorsSeries B, Series C, Series D, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 16, 2026

    Roy W. Ware joins to lead CMSC operations for therapeutics pipeline.

  • Jan 7, 2026

    Will present at the 44th Annual J.P. Morgan Healthcare Conference.

Artios Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Artios Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Artios Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range125
Year Founded2016
Last FundingNov 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.